New immune drug tested in patients who have run out of options
NCT ID NCT05614258
Summary
This is a very early, first-in-human study to test the safety of a new drug called ADG206. It is enrolling 14 people with advanced or metastatic solid tumors that have progressed after all standard treatments. The main goal is to find a safe dose and see how the body handles the drug, which is designed to activate the immune system to fight cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED/METASTATIC SOLID TUMORS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Ashford Cancer Centre Research
Kurralta Park, South Australia, 5037, Australia
-
Monash Health
Clayton, Victoria, 3168, Australia
Conditions
Explore the condition pages connected to this study.